fluorouracil has been researched along with er-086526 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Shaughnessy, JA; Perez, EA; Rugo, HS | 2 |
| Avancha, K; Glück, S; Lopes, G; Montero, AJ | 1 |
| Adachi, Y; Aoshima, K; Asano, M; Funahashi, Y; Kawano, S; Kimura, T; Matsui, J; McCracken, PJ; Nomoto, K; Oda, Y; Okamoto, K; Ozawa, Y; Semba, T; Tizon, X; Tohyama, O; Uehara, T; Uesugi, M; Watanabe, H | 1 |
| Awada, A; Cortes, J; He, Y; Kaufman, PA; Olivo, M; Twelves, C; Vahdat, L | 1 |
| Awada, A; Cortes, J; Dutcus, CE; He, Y; Kaufman, PA; Olivo, MS; Perez, EA; Twelves, C; Velikova, G; Yelle, L | 1 |
| Hirakawa, K; Ikeda, K; Ishikawa, T; Kashiwagi, S; Kawajiri, H; Kudoh, S; Mizuyama, Y; Nishimori, T; Nishimura, S; Noda, S; Ogawa, Y; Ohira, M; Onoda, N; Sunami, T; Takada, M; Takashima, T; Tei, S; Tezuka, K; Tokunaga, S; Yamagata, S | 1 |
| Fujimoto, Y; Ishiguro, H; Kagimura, T; Kang, Y; Kato, T; Kikawa, Y; Kotake, T; Moriguchi, Y; Nakatsukasa, K; Nakayama, I; Ogura, N; Okuno, T; Sugie, T; Suwa, H; Taguchi, T; Takada, M; Takahara, S; Toi, M; Tsuyuki, S; Yamagami, K; Yamashiro, H; Yasuoka, R; Yoshibayashi, H | 1 |
| Altundag, K | 1 |
| Akazawa, K; Hasegawa, Y; Hayashi, M; Horiguchi, J; Ishikawa, T; Kohno, N; Kubota, T; Miura, D; Miyashita, M; Narui, K; Suzuki, M; Tachibana, A; Yamada, A; Yamada, K | 1 |
4 trial(s) available for fluorouracil and er-086526
| Article | Year |
|---|---|
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Furans; Humans; Ketones; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids | 2014 |
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Middle Aged; Taxoids; Young Adult | 2015 |
An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Fluorouracil; Follow-Up Studies; Furans; Humans; Ketones; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptor, ErbB-2; Retreatment; Survival Rate | 2021 |
A Randomized Controlled Phase 2 Study of Neoadjuvant Eribulin Versus Paclitaxel in Women with Operable Breast Cancer: The JONIE-3 Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome | 2022 |
6 other study(ies) available for fluorouracil and er-086526
| Article | Year |
|---|---|
Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Receptor, ErbB-2; Taxoids; Tubulin Modulators; Vascular Endothelial Growth Factor A | 2011 |
Current treatment options for metastatic breast cancer: what now?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Tubulin Modulators | 2011 |
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Decision Making, Computer-Assisted; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Furans; Humans; Ketones; Markov Chains; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
Topics: Animals; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Furans; Humans; Ketones; Mice, Inbred BALB C; Tubulin Modulators; Tumor Microenvironment; Vascular Remodeling; Xenograft Model Antitumor Assays | 2014 |
Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; Furans; Hormones; Humans; Ketones; Prospective Studies; Receptor, ErbB-2; Taxoids | 2022 |
Combination Treatment of Vinorelbine With Oral Cyclophosphamide or Capecitabine or Both Might Overcome Cross-resistance Against Eribulin in Advanced Breast Cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Female; Fluorouracil; Furans; Humans; Ketones; Treatment Outcome; Vinblastine; Vinorelbine | 2022 |